MCID: INT002
MIFTS: 64

Intermittent Claudication

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 39 12 56 45 15 74
Amyotrophic Lateral Sclerosis 74
Charcot's Syndrome 12
Charcot Disease 77

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
MeSH 45 D007383
SNOMED-CT 69 63491006
ICD10 34 I73.9

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as amyotrophic lateral sclerosis, is related to peripheral artery disease and ischemia, and has symptoms including seizures, tremor and polydipsia. An important gene associated with Intermittent Claudication is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Paclitaxel and Glimepiride have been mentioned in the context of this disorder. Affiliated tissues include Placenta, brain and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 77 Charcot–Marie–Tooth disease (CMT) is one of the hereditary motor and sensory neuropathies, a group of... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.0 ACE CRP IL6 SELP VEGFA
2 ischemia 31.1 ACE SELP VEGFA
3 critical limb ischemia 30.9 IL6 VEGFA
4 angina pectoris 30.2 ACE CRP IL6 SERPINC1
5 carotid stenosis 30.0 ACE CRP SELP
6 arteriovenous fistula 30.0 APOH IL6
7 limb ischemia 30.0 ACE ANGPT2 IL6 VEGFA VWF
8 arteriosclerosis 29.9 ACE CRP IL6 SELP SERPINE1
9 systolic heart failure 29.8 ACE CRP IL6
10 coronary artery anomaly 29.7 ACE CRP F2 SELP SERPINE1
11 coronary heart disease 1 29.6 ACE CRP IL6 SELP SERPINE1
12 temporal arteritis 29.6 APOH CRP IL6
13 diabetes mellitus 29.5 ACE ALB CRP IL6 SERPINE1 VEGFA
14 hypertension, essential 29.5 ACE ALB SELP SERPINE1 VWF
15 polyarteritis nodosa 29.4 APOH CRP IL6
16 arteries, anomalies of 29.2 ACE ALB CRP IL6 SELP SERPINC1
17 thrombosis 29.1 APOH F2 SELP SERPINC1 SERPINE1 VWF
18 thrombophilia 29.0 APOH F2 SERPINC1 SERPINE1 VWF
19 diabetes mellitus, noninsulin-dependent 28.9 ACE ALB CRP IL6 SERPINE1 VWF
20 infective endocarditis 28.8 APOH CRP F2 IL6 SERPINE1
21 myocardial infarction 28.3 ACE ALB CRP F2 IL6 SELP
22 endocarditis 28.3 ALB APOH CRP F2 IL6 SERPINC1
23 heart disease 28.3 ACE ALB CRP F2 IL6 SELP
24 systemic lupus erythematosus 28.0 ACE ALB APOH CRP F2 IL6
25 peripheral vascular disease 28.0 ACE ALB CRP F2 IL6 SELP
26 vascular disease 27.5 ACE ALB APOH CRP F2 IL6
27 amyotrophic lateral sclerosis 1 11.6
28 juvenile amyotrophic lateral sclerosis 11.4
29 spinal stenosis 10.5
30 carotid artery thrombosis 10.5 SELP SERPINE1
31 infiltrating angiolipoma 10.5 VEGFA VWF
32 hypertensive retinopathy 10.4 ACE VWF
33 japanese spotted fever 10.4 CRP SERPINC1
34 aspirin allergy 10.4 SERPINC1 SERPINE1
35 argentine hemorrhagic fever 10.4 SERPINC1 SERPINE1
36 sticky platelet syndrome 10.4 SERPINC1 SERPINE1
37 pyuria 10.4 ALB CRP
38 gastrointestinal tuberculosis 10.4 ALB CRP
39 decubitus ulcer 10.4 ALB CRP
40 brachydactyly, type d 10.3 F2 VWF
41 factor viii deficiency 10.3 F2 VWF
42 von willebrand disease, type 1 10.3 F2 VWF
43 acroosteolysis 10.3 ALB VEGFA
44 active peptic ulcer disease 10.3 F2 VWF
45 renal artery obstruction 10.3 ACE SERPINC1
46 severe nonproliferative diabetic retinopathy 10.3 ALB VEGFA
47 coronary restenosis 10.3 ACE SERPINC1
48 ischemic neuropathy 10.3 CRP F2
49 chronic thromboembolic pulmonary hypertension 10.3 CRP F2
50 cryptogenic cirrhosis 10.3 F2 SERPINE1

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):


Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


seizures, tremor, polydipsia, fatigue, edema, back pain, pain, headache, syncope, cyanosis, chronic pain, sciatica, asthenia, chills, signs and symptoms, signs and symptoms, digestive, hot flushes, vertigo/dizziness, sleeplessness, eye manifestations, oral manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, signs and symptoms, respiratory, skin manifestations, renal colic, mobility limitation, prodromal symptoms, medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 ACE ANGPT2 CRP F2 IL6 SELP
2 homeostasis/metabolism MP:0005376 10.15 ACE ALB ANGPT2 APOH CRP F2
3 immune system MP:0005387 10.02 ACE ANGPT2 CRP F2 IL6 SELP
4 hematopoietic system MP:0005397 10.01 ACE F2 IL6 SELP SERPINC1 SERPINE1
5 digestive/alimentary MP:0005381 9.98 ALB ANGPT2 F2 HTR2A IL6 VEGFA
6 mortality/aging MP:0010768 9.9 ACE ALB ANGPT2 APOH F2 IL6
7 liver/biliary system MP:0005370 9.8 ACE ALB IL6 SELP SERPINC1 SERPINE1
8 renal/urinary system MP:0005367 9.5 ACE ALB IL6 SELP SERPINC1 SERPINE1
9 respiratory system MP:0005388 9.1 ANGPT2 F2 IL6 SELP SERPINE1 VEGFA

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 494)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
2
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
3
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
4
Gliclazide Approved Phase 4 21187-98-4 3475
5
Glyburide Approved Phase 4 10238-21-8 3488
6
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 111025-46-8 4829
7
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
8
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2 6493-05-6 4740
9
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
10
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
11
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
12
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
13
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
14
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
15
Losartan Approved Phase 4 114798-26-4 3961
16
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1744-22-5 5070
17
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2 745-65-3 149351 5280723
18
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
19
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
20
Simvastatin Approved Phase 4,Phase 2,Not Applicable 79902-63-9 54454
21
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable 58-61-7 60961
22
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Not Applicable 274693-27-5 9871419
23
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
24
Allopurinol Approved Phase 4 315-30-0 2094
25
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
26
Ramipril Approved Phase 4 87333-19-5 5362129
27
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
28
Histamine Approved, Investigational Phase 4,Phase 1 51-45-6 774
29
Promethazine Approved, Investigational Phase 4 60-87-7 4927
30
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable 1177-87-3
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
33
Amlodipine Approved Phase 4 88150-42-9 2162
34
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 134523-00-5 60823
35
Nicotinamide Approved, Investigational Phase 4,Phase 3,Not Applicable 98-92-0 936
36
Ezetimibe Approved Phase 4 163222-33-1 150311
37
Mexiletine Approved, Investigational Phase 4,Phase 2 31828-71-4 4178
38
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
39
Thrombin Approved, Investigational Phase 4
40
Verapamil Approved Phase 4,Phase 2 52-53-9 2520
41
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1401-55-4
42
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
43
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
44
Vorapaxar Approved Phase 4 618385-01-6
45
Ranolazine Approved, Investigational Phase 4,Phase 2,Not Applicable 142387-99-3, 95635-55-5 56959
46
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
47
Acetaminophen Approved Phase 4 103-90-2 1983
48
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
50
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 978)
# Name Status NCT ID Phase Drugs
1 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion Unknown status NCT00407940 Phase 4
2 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis Unknown status NCT02033135 Phase 4
3 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
4 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
5 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
6 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
7 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
8 Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) Completed NCT00906022 Phase 4
9 Neurogenic Intermittent Claudication Evaluation Study Completed NCT00905359 Phase 4
10 Evaluation of Cilostazol in Combination With L-Carnitine Completed NCT00822172 Phase 4 cilostazol
11 Intermittent Neurogenic Claudication Treatment With APERIUS® Completed NCT00887744 Phase 4
12 A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
13 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
14 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
15 Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE) Completed NCT00883246 Phase 4
16 Angioplasty in Peripheral Arterial Disease and Endothelial Function Completed NCT00660634 Phase 4
17 PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Completed NCT00715416 Phase 4
18 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Completed NCT00300690 Phase 4
19 4-EVER : a Trial Investigating the Safety of 4F Endovascular Treatment of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
20 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
21 DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
22 Lumbar Stenosis Outcomes Research (LUSTOR) Completed NCT00638443 Phase 4 Pregabalin;Diphenhydramine
23 The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD) Completed NCT00189618 Phase 4 Aspirin;Clopidogrel
24 Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions Completed NCT00764777 Phase 4
25 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
26 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4 Control
27 Arterial Inflow and Muscle Ischemia During Calf Stimulation With the Veinoplus Device Completed NCT01592812 Phase 4
28 Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
29 Peripheral Vascular Disease and Nerve Stimulation Completed NCT01942941 Phase 4
30 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study Completed NCT00228384 Phase 4
31 Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors Completed NCT00407537 Phase 4 Amlodipine besylate/atorvastatin calcium single pill combination
32 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed NCT00687076 Phase 4 Ezetimibe;Niaspan;Statin therapy;Aspirin;Clopidogrel;Placebo Niaspan;Placebo Ezetimibe
33 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
34 CARE Canadian ALS Riluzole Evaluation Completed NCT00542412 Phase 4 Riluzole
35 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
36 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
37 Modafinil for Treatment of Fatigue in ALS Patients Completed NCT00614926 Phase 4 Modafinil;Placebo
38 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
39 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Recruiting NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
40 Ramipril Treatment of Claudication Recruiting NCT02842424 Phase 4 Ramipril
41 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Recruiting NCT02807779 Phase 4 Dexamethasone infusion
42 Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease Not yet recruiting NCT03493412 Phase 4 Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin);Placebo
43 The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
44 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Terminated NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
45 Cilostazol After Lower Extremity Arterial Revascularization Trial Terminated NCT02374957 Phase 4 Cilostazol
46 Ticagrelor and Peripheral Arterial Disease Terminated NCT02407314 Phase 4 Aspirin;Aspirin + Ticagrelor
47 Condition of Approval Study Terminated NCT00517751 Phase 4
48 Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant Terminated NCT01057641 Phase 4
49 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
50 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Terminated NCT01901224 Phase 4 Metformin 1000 mg;Placebo

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

42
Brain, Testes, Bone, Spinal Cord, Endothelial, Skeletal Muscle, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 4093)
# Title Authors Year
1
Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging. ( 30740050 )
2019
2
Harnessing cellular aging in human stem cell models of amyotrophic lateral sclerosis. ( 30565851 )
2019
3
Assessing Anxiety and its correlates in Amyotrophic Lateral Sclerosis: the State-Trait Anxiety Inventory. ( 30897219 )
2019
4
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. ( 30859373 )
2019
5
Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. ( 30586555 )
2019
6
A juvenile sporadic amyotrophic lateral sclerosis case with P525L mutation in the FUS gene: A rare co-occurrence of autism spectrum disorder and tremor. ( 30684766 )
2019
7
Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. ( 30911572 )
2019
8
HR23B pathology preferentially co-localizes with p62, pTDP-43 and poly-GA in C9ORF72-linked frontotemporal dementia and amyotrophic lateral sclerosis. ( 30867060 )
2019
9
Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. ( 30763568 )
2019
10
Twin CHCH Proteins, CHCHD2, and CHCHD10: Key Molecules of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. ( 30791515 )
2019
11
Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )
2019
12
Depression and risk of Cognitive Dysfunctions in Amyotrophic Lateral Sclerosis. ( 30712314 )
2019
13
A case of amyotrophic lateral sclerosis which was diagnosed with progressive dysphagia and muscle atrophy. ( 30631656 )
2019
14
GABAB receptor encephalitis in a patient diagnosed with amyotrophic lateral sclerosis. ( 30871492 )
2019
15
Three-curve rocker-soled shoes and gait adaptations to intermittent claudication pain: A randomised crossover trial. ( 30265963 )
2019
16
Remote Ischemic Pre-conditioning in the Management of Intermittent Claudication: A Pilot Randomized Controlled Trial. ( 30278263 )
2019
17
Effect of Annurca Apple Polyphenols on Intermittent Claudication in Patients With Peripheral Artery Disease. ( 30573159 )
2019
18
Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status. ( 30626552 )
2019
19
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. ( 30630355 )
2019
20
A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. ( 30777692 )
2019
21
Protocol for a prospective, longitudinal cohort study on the effect of arterial disease level on the outcomes of supervised exercise in intermittent claudication: the ELECT Registry. ( 30782932 )
2019
22
A multicenter randomized controlled study to evaluate whether neuromuscular electrical stimulation improves the absolute walking distance in patients with intermittent claudication compared with best available treatment. ( 30792054 )
2019
23
Supervised exercise therapy and revascularization: Single-center experience of intermittent claudication management. ( 30795714 )
2019
24
VAPB depletion alters neuritogenesis and phosphoinositide balance in motoneuron-like cells: relevance to VAPB-linked ALS. ( 30745341 )
2019
25
Response to Letter to the Editor: "Amyotrophic lateral sclerosis and exposure to diesel exhaust in a Danish cohort". ( 30753256 )
2019
26
High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. ( 30760645 )
2019
27
Muscle secretion of toxic factors, regulated by miR126-5p, facilitates motor neuron degeneration in amyotrophic lateral sclerosis. ( 30762002 )
2019
28
Corrigendum to "Driven to decay: Excitability and synaptic abnormalities in amyotrophic lateral sclerosis" [Brain Research Bulletin 140 (2018) 318-333]. ( 30770039 )
2019
29
Contact Sports as a Risk Factor for Amyotrophic Lateral Sclerosis: A Systematic Review. ( 30775214 )
2019
30
Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30782181 )
2019
31
Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. ( 30784318 )
2019
32
TDP-43: A KEY THERAPEUTIC TARGET BEYOND AMYOTROPHIC LATERAL SCLEROSIS. ( 30785719 )
2019
33
Smoking and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. ( 30786056 )
2019
34
Physicians' attitudes toward end-of-life decisions in amyotrophic lateral sclerosis. ( 30789031 )
2019
35
Regional dynamics of the resting brain in amyotrophic lateral sclerosis using fALFF and ReHo analyses. ( 30793923 )
2019
36
Tract integrity in amyotrophic lateral sclerosis: 6-month evaluation using MR diffusion tensor imaging. ( 30795741 )
2019
37
Excitability in somatosensory cortex correlates with motoric impairment in amyotrophic lateral sclerosis. ( 30798637 )
2019
38
Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. ( 30807321 )
2019
39
Study on variation trend of repetitive nerve stimulation waveform in amyotrophic lateral sclerosis. ( 30807353 )
2019
40
Edaravone for the treatment of amyotrophic lateral sclerosis. ( 30810406 )
2019
41
Analysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1G93A mouse model of amyotrophic lateral sclerosis. ( 30811816 )
2019
42
Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. ( 30811981 )
2019
43
A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. ( 30814647 )
2019
44
Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. ( 30816241 )
2019
45
Psychological flexibility and attitudes toward evidence-based interventions by amyotrophic lateral sclerosis patients. ( 30828499 )
2019
46
Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. ( 30837838 )
2019
47
Information-domain method for the quantification of the complexity of the sympathetic baroreflex regulation in healthy subjects and amyotrophic lateral sclerosis patients. ( 30840931 )
2019
48
Amyotrophic Lateral Sclerosis: The Assessment of Inspiratory Muscle Failure. ( 30846202 )
2019
49
Comparison of the clinical and genetic features of amyotrophic lateral sclerosis across Cuban, Uruguayan and Irish clinic-based populations. ( 30846540 )
2019
50
A near miss: Autonomic dysfunction in a 2% total burn surface area burn patient with ventilator-dependent amyotrophic lateral sclerosis. ( 30847184 )
2019

Variations for Intermittent Claudication

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

Pathways related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.35 ALB ANGPT2 APOH F2 SELP SERPINC1
2 11.87 HTR2A IL6 VEGFA
3
Show member pathways
11.87 F2 SERPINC1 SERPINE1 VWF
4 11.73 ALB IL6 VEGFA
5 11.7 F2 SERPINC1 SERPINE1 VWF
6
Show member pathways
11.69 ALB CRP F2 IL6 SERPINE1
7 11.58 IL6 SERPINE1 VEGFA
8 11.46 ANGPT2 IL6 SERPINE1 VEGFA
9 11.07 ANGPT2 SERPINE1 VEGFA
10 10.89 ANGPT2 SERPINE1
11 10.74 CRP IL6

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 ACE ALB APOH F2 SERPINC1 SERPINE1
2 extracellular region GO:0005576 9.7 ACE ALB ANGPT2 APOH CRP F2
3 endoplasmic reticulum lumen GO:0005788 9.62 ALB F2 IL6 SERPINC1
4 blood microparticle GO:0072562 9.58 ALB F2 SERPINC1
5 collagen-containing extracellular matrix GO:0062023 9.56 APOH SERPINC1 SERPINE1 VWF
6 platelet alpha granule lumen GO:0031093 9.46 ALB SERPINE1 VEGFA VWF
7 extracellular space GO:0005615 9.36 ACE ALB ANGPT2 APOH CRP F2

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 F2 IL6 SERPINE1 VEGFA
2 cellular protein metabolic process GO:0044267 9.76 ALB F2 IL6 SERPINC1
3 positive regulation of angiogenesis GO:0045766 9.74 ANGPT2 SERPINE1 VEGFA
4 platelet activation GO:0030168 9.72 F2 IL6 VWF
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 HTR2A IL6 VEGFA
6 defense response to Gram-negative bacterium GO:0050829 9.69 IL6 SELP SERPINE1
7 hemostasis GO:0007599 9.61 F2 SERPINC1 VWF
8 fibrinolysis GO:0042730 9.58 F2 SERPINE1
9 negative regulation of blood coagulation GO:0030195 9.56 APOH SERPINE1
10 positive regulation of leukocyte migration GO:0002687 9.54 SELP VEGFA
11 acute-phase response GO:0006953 9.54 CRP F2 IL6
12 blood coagulation, intrinsic pathway GO:0007597 9.5 APOH F2 VWF
13 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
14 neutrophil mediated immunity GO:0002446 9.48 ACE IL6
15 positive regulation of blood coagulation GO:0030194 9.43 APOH F2 SERPINE1
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.4 ACE VEGFA
17 regulation of blood coagulation GO:0030193 9.33 APOH F2 SERPINC1
18 negative regulation of fibrinolysis GO:0051918 9.13 APOH F2 SERPINE1
19 platelet degranulation GO:0002576 9.1 ALB APOH SELP SERPINE1 VEGFA VWF

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB APOH CRP SERPINC1 VEGFA VWF
2 growth factor activity GO:0008083 9.5 F2 IL6 VEGFA
3 protease binding GO:0002020 9.43 SERPINC1 SERPINE1 VWF
4 drug binding GO:0008144 9.13 ACE ALB HTR2A
5 heparin binding GO:0008201 9.02 APOH F2 SELP SERPINC1 VEGFA

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....